Oncotarget

Research Papers:

EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway

Ke-Wang Luo _, Wing-Yin Lung, Chun-Xie  , Xin-Le Luo and Wei-Ren Huang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:12261-12272. https://doi.org/10.18632/oncotarget.24301

Metrics: PDF 1322 views  |   HTML 2127 views  |   ?  


Abstract

Ke-Wang Luo1,2, Wing-Yin Lung2, Chun-Xie1, Xin-Le Luo1 and Wei-Ren Huang2

1Key Laboratory, People’s Hospital of Longhua, Shenzhen, China

2Key Laboratory of Medical Programming Technology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China

Correspondence to:

Xin-Le Luo, email: luoxinlesz@163.com

Wei-Ren Huang, email: pony8089@163.com

Keywords: EGCG; bladder cancer; T24; 5637; PI3K/AKT

Received: September 29, 2017     Accepted: November 13, 2017     Published: January 16, 2018

ABSTRACT

Epigallocatechin-3-gallate (EGCG), the bioactive polyphenol in green tea, has been demonstrated to have various biological activities. We previously found that EGCG inhibited SW780 tumor growth by down-regulation of NF-κB and MMP-9. This study demonstrated that EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway, without modulation of NF-κB. Our results showed that treatment of EGCG resulted in significant inhibition of cell proliferation by induction of apoptosis, without obvious toxicity to normal bladder SV-HUC-1 cells. EGCG also inhibited 5637 and T24 cell migration and invasion at 25–100 μM. Western blot confirmed that EGCG induced apoptosis in T24 and 5637cells by activation of caspases-3 and PARP. Besides, EGCG up-regulated PTEN and decreased the expression of phosphorylated PI3K, AKT in both T24 and 5637 cells. In addition, animal study demonstrated that EGCG (100 mg/kg, i.p. injected daily for 4 weeks) decreased the tumor weight in mice bearing T24 tumors by 51.2%, as compared with the untreated control. EGCG also decreased the expression of phosphorylated PI3K and AKT in tumor, indicating the important role of PI3K/AKT in EGCG inhibited tumor growth. When AKT was inhibited, EGCG showed no obvious effect in cell migration in T24 and 5637 cells. In conclusion, our study elucidated that EGCG was effective in inhibition of T24 and 5637 cell proliferation and migration, and presented evidence that EGCG inhibited cell proliferation and tumor growth by modulation of PI3K/AKT pathway.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24301